Related Experiment Video
Updated: May 24, 2026
07:10
Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
How I treat HIV-associated lymphoma
Kieron Dunleavy1, Wyndham H Wilson
1Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA. dunleavk@mail.nih.gov
Blood
|February 17, 2012
Summary
Significant advancements in treating HIV-associated lymphomas have led to high cure rates, especially with combination antiretroviral therapy and rituximab. Future research will focus on complex cases and novel therapies.
Area of Science:
- Oncology
- Infectious Diseases
- Immunology
Background:
- HIV-associated lymphomas have seen significant progress in understanding and treatment over the last decade.
- Combination antiretroviral therapy (cART) has dramatically improved patient prognoses.
Purpose of the Study:
- To review the progress in understanding and treating HIV-associated lymphomas.
- To highlight the effectiveness of current therapies and identify future research directions.
Main Methods:
- Review of recent studies and therapeutic strategies for HIV-associated lymphomas.
- Analysis of treatment outcomes in the cART era.
Main Results:
- Most patients with HIV-associated lymphomas, including diffuse large B-cell lymphoma and Burkitt lymphoma, can now be cured.
- Rituximab has shown a significant role in improving outcomes for these patients.
- Curability rates for many HIV-associated lymphomas now approach those of HIV-negative counterparts.
Conclusions:
- Current therapeutic strategies, including cART and rituximab, have made HIV-associated lymphomas highly curable.
- Future research should target improving outcomes for patients with advanced immune suppression and adverse tumor biology.
- Novel targeted agents and combination chemotherapy regimens are needed for future clinical trials.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.